Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, By Distribution Channel, By Geography

Description

Relapsed or Refractory Diffuse Large B-cell Lymphoma Market is estimated to be valued at USD 1,610.0 Mn in 2025 and is expected to reach USD 2,161.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,610.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.30%	2032 Value Projection:	USD 2,161.8 Mn

Market players are focusing on developing effective therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma which is expected to fuel the market growth over the forecast period. For instance, in November 2020, ADC Therapeutics SA, a late clinical-stage biotechnology company, announced that its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) had been accepted by the U.S. Food and Drug Administration (FDA). Lloncastuximab tesirine (Lonca) is developed for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Moreover, in December 2020, Novartis AG, announced analyses of a 40-month median follow-up from the Phase II JULIET trial, according to which Kymriah, a CAR-T cell therapy, showed safety and efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations and agreements in order to strengthen their market presence which is anticipated to drive the growth of relapsed or refractory diffuse large B-cell lymphoma market. For instance, on June 10, 2020, AbbVie Inc., a publicly traded biopharmaceutical company and Genmab A/S, a biotechnology company, signed a collaboration agreement to develop and commercialize Genmab's early-stage investigational antibody product candidates for cancer. Under this agreement, the companies will commercialize epcoritamab, indicated for B cell malignancies such as diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

Similarly, on June 29, 2020, Karyopharm Therapeutics, Inc., a pharmaceutical company, selected Biologics by McKesson, an independent specialty pharmacy by McKesson Corporation, as a specialty pharmacy provider for XPOVIO, indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)

Key features of the study:

This report provides in-depth analysis of the global relapsed or refractory diffuse large B-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global relapsed or refractory diffuse large B-cell lymphoma market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global relapsed or refractory diffuse large B-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B-cell Lymphoma market.

Detailed Segmentation:

Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type:
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- MorphoSys US Inc.
- Bristol Myers Squibb
- Karyopharm Therapeutics
- Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG

Product Code: CMI4426

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Trends
Recent Product Launches/Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- MorphoSys US Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Karyopharm Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Merck & Co., Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Gilead Sciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Regeneron Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cellular Biomedicine Group Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Genmab A/S
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Incyte
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Janssen Biotech, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- IMV Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Overland Pharmaceuticals (CY) Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- ADC Therapeutics SA
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eagle Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Adaptive Biotechnologies Corporation
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
  - Analysts' Views

9. Section

References
Research Methodology
About us and Sales Contact